Domestic pharmaceutical firms lined up to enter generic amlodipine market

The Korean government policy to offer preferential treatment for generic and bioequivalence-tested drugs has prompted a number of domestic pharmaceutical firms to flock to the domestic generic amlodipine market, where Pfizer Korea's Norvasc (amlodipine besylate) has held on to its market dominance with sizable sales of more than 150 billion last year.

Notably, SK Pharm and Hanmi Pharm have b...